Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Michigan

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Awareness

For decades, the public health landscape has been shaped by broad initiatives aimed at improving general wellness and disseminating accessible medical knowledge. This legacy of general health and science information has empowered individuals to make informed decisions about preventive care and chronic disease management. Within this context, pharmaceutical interventions have played a central role, with medications like bisphosphonates becoming widely prescribed for conditions such as osteoporosis. As awareness of medication side effects grew, the focus shifted from general health promotion to specific, serious adverse events linked to long-term drug exposure. One such concern involves the association between bisphosphonate use and osteonecrosis of the jaw, a condition that has prompted legal and medical scrutiny. This transition from a general health framework to a targeted occupational and pharmaceutical exposure concern is particularly relevant in mass production settings, where workers may face prolonged contact with raw materials or finished products. The shift requires careful consideration of how historical health information now informs risk assessment for specific populations, including those in manufacturing environments. By bridging the gap between broad health education and focused exposure analysis, stakeholders can better address the implications of pharmaceutical agents in both clinical and occupational contexts.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a serious adverse event reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Presentation and Mechanisms of Fosamax-Related ONJ

The clinical presentation of ONJ involves exposed, necrotic bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, and it requires exclusion of metastatic disease. The mechanistic pathways linking Fosamax to ONJ are not fully understood, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates inhibit osteoclast activity, reducing bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local infections or trauma. This is particularly relevant in the jaw, which has high bone turnover and is subject to frequent mechanical stress and dental procedures. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Legal Considerations for Michigan Patients: Statute of Limitations

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the warning does not specify a precise timeline for onset, and the variability in symptom onset (from one day to several months) may complicate patient awareness and early detection. The label also advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients in Michigan, attorney-related considerations involve the statute of limitations for filing a product liability claim. In Michigan, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Given the variable timeline between Fosamax exposure and documented harm—ranging from days to months—patients must be vigilant about documenting the onset of symptoms and any dental procedures that may have triggered ONJ. The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so patients who have been on Fosamax for several years should be particularly aware of potential jaw symptoms. In summary, Fosamax is associated with a risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures or concomitant therapies. The timeline for symptom onset is variable, and discontinuation of the drug may reduce risk. Patients in Michigan who develop ONJ after Fosamax use should consult with an attorney to understand the applicable statute of limitations and ensure timely filing of any claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Michigan?

In Michigan, the statute of limitations for personal injury claims, including those related to defective drugs like Fosamax, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Given the variable onset of ONJ symptoms, it is crucial to document the timeline of exposure and symptoms promptly.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.